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Glucocorticoids (GCs) induce apoptosis in lymphocytes and are effective agents for the 
treatment of leukemia.  The activated glucocorticoid receptor (GR) initiates a transcriptional 
program leading to caspase activation and cell death, but the critical signaling intermediates in 
GC-induced apoptosis remain largely undefined.  We have observed that GC induction of the 
three major protein products of the Bcl-2 relative Bim (BimEL, BimS and BimL) correlates with 
GC sensitivity in a panel of human pre-B acute lymphoblastic leukemia (ALL) cell lines.  To test 
the hypothesis that Bim facilitates GC-induced apoptosis, we reduced BIM mRNA levels and 
Bim protein levels by RNA interference (RNAi) in highly GC-sensitive pre-B ALL cells.  
Reducing Bim proteins by either electroporation of synthetic siRNA duplexes or lentiviral-
mediated stable expression of shRNA inhibited activation of caspase-3 and increased cell 
viability following GC exposure.  We also observed that the extent of GC resistance correlated 
with siRNA silencing potency.  siRNA duplexes that reduced only BimEL or BimEL and BimL 
(but not BimS) exhibited less GC resistance than a potent siRNA that silenced all three major 
isoforms, implying that induction of all three Bim proteins contributes to cell death.  Finally, the 
modulation of GC-induced apoptosis caused by Bim silencing was independent of Bcl-2 
expression levels, negating the hypothesis that the ratio of Bim to Bcl-2 regulates apoptosis.  
These results offer evidence that induction of Bim by GC is a required event for the complete 
apoptotic response in pre-B ALL cells. 
 





Glucocorticoids (GCs)1 are steroid hormones that maintain physiological homeostasis.  
Synthetic GCs such as dexamethasone and triamcinolone acetonide (TA) are widely prescribed 
pharmaceuticals for indications ranging from inflammation to cancer.  GCs induce apoptosis in 
numerous lymphoid and myeloid tissues, and have been successful in the treatment of childhood 
leukemias (1).  The mechanism of GC-induced apoptosis involves the hallmarks of the intrinsic 
pathway of apoptosis: release of cytochrome c and Smac from the mitochondria and activation of 
caspase-9 (2).  Determining the molecular trigger(s) that commit the cell to activation of intrinsic 
apoptosis might enable strategies to combat GC-resistant leukemias.  Precursor B-cell (pre-B) 
acute lymphoblastic leukemia (ALL) is the most common childhood cancer and a useful model 
to investigate the mechanism of GC-induced apoptosis (3).   
GC signaling occurs through the glucocorticoid receptor (GR), a nuclear receptor 
superfamily member that dissociates from a large Hsp70-containing complex and translocates to 
the nucleus upon GC binding, reviewed in (4).  The activated GR initiates a tissue-specific 
transcriptional program through both direct DNA binding and interaction with other transcription 
 
1 Abbreviations: ALL, acute lymphoblastic leukemia; BH3, Bcl-2 homology domain 3; GC, 
glucocorticoid; GFP, green fluorescent protein; GR, glucocorticoid receptor; DAPI, 4',6-
Diamidino-2-phenylindole; µF, microfarads; PBS, phosphate-buffered saline; 7-AAD, 7-
aminoactinomycin D; TA, triamcinolone acetonide; RNAi, RNA interference; RT-PCR, reverse 
transcriptase-polymerase chain reaction; siRNA, small-interfering RNA; shRNA, short hairpin 
RNA; Smac, second mitochondria-derived activator of caspase. 
 
BIM RNAi and Glucocorticoid-Induced Apoptosis                                       WICKSTROM, Eric 
 
4
factors.  Numerous studies with actinomycin D and cycloheximide have demonstrated that new 
transcription and protein synthesis, respectively, are required for GC-induced apoptosis (5,6).  
Microarray profiling has shown that a short GC exposure induces or represses transcription of 
over 100 genes by a factor of 3-fold or greater in multiple models of GC-induced apoptosis (7-9).  
Among these genes are universal regulators of intrinsic apoptosis, such as BCL2, and BIM, a
gene encoding several splice variants of the related BH3 (Bcl-2 homology region 3)-domain 
containing protein Bim (7,9).  GC represses BCL2 transcription, but induces BIM transcription.  
Lymphocytes containing overexpressed (7) or high endogenous levels (10) of Bcl-2 protein are 
partially GC-resistant, underscoring the significance of intrinsic pathway regulation in GC 
signaling.  Bim protein is in the”BH3-only” (Bcl-2 homology-3) subset of Bcl-2 relatives, a 
group that also includes Bid, Bad, Puma, and Noxa.  BH3-only proteins are transcriptionally 
activated, post-translationally modified or released from sequestration in response to death 
stimuli, and promote apoptosis by interacting with Bcl-2 family members that contain multiple 
BH domains (BH1-BH4), reviewed in (11).   
Bim is a critical regulator of immune cell homeostasis as well as apoptosis in several 
tissue types, and has been recently investigated in preclinical models as a potential cancer 
therapeutic (12,13).  Mice lacking Bim contain strikingly high numbers of leukocytes and 
eventually succumb to autoimmune disease (14).  Importantly, thymocytes isolated from these 
mice demonstrate a delayed apoptotic response to the GC dexamethasone (14).  Loss of a single 
allele of BIM accelerated the rate of murine c-myc-induced lymphoma development, leading to 
classification of Bim as a tumor suppressor protein (15).   Bim expression is induced by growth 
factor withdrawal (16,17), T-cell receptor ligation (18), paclitaxel treatment (19) and forced 
growth in suspension (20,21) in various cell types, suggesting that transcriptional regulation of 
Bim is an upstream event in apoptosis induced by diverse stimuli.  Finally, lowering BIM mRNA 
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by RNAi causes partial protection against apoptosis induced by the drugs paclitaxel (19) and 
imitinib (22), as well as apoptosis induced by forced suspension culture (anoikis) (20,21). 
 The BIM gene is transcribed as three major spice variants: BIM EL, BIM L, and BIM S,
encoding the functionally-distinct proteins BimEL, BimL, and BimS, respectively (23).  BimS 
protein has been widely reported to be the most strongly pro-apoptotic of the three, although 
there may be exceptions (16).  Only BimEL is likely to be regulated by phosphorylation and 
caspase-3 cleavage (24).  Both BimEL and BimL (but not BimS) may be sequestered by LC8, a 
subunit of the dynein motor complex (25), though the significance of this interaction has recently 
been questioned (26).   
Previous studies in our laboratory (7) and others (9,27) have led to speculation that 
transcriptional induction of Bim is required for GC-induced apoptosis.  Only correlative 
evidence has thus far been generated in leukemic cells.  In order to test this hypothesis directly, 
we used RNA interference (RNAi) (28) to reduce BIM mRNA levels and found that both 
synthetic siRNAs and lentiviral-expressed shRNAs rendered human 697 pre-B ALL cells 
partially resistant to GC and inhibited GC-induced caspase-3 activity.  Using splice variant-
specific siRNAs, we found that all three major isoforms contribute to GC-induced apoptosis.  
Finally, we demonstrate that the Bim/Bcl-2 ratio is not a critical parameter in this pathway, 
suggesting that Bim functions primarily in a Bcl-2-independent manner in pre-B ALL cells. 
 
Materials and Methods 
 
Cell culture and reagents.  The pre-B ALL cells lines were cultured in RPMI-1640 medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen).  
Nalm-6, Kasumi-2, and Kopn-8 cells were acquired from DSMZ (Braunschweig, Germany). 
Triamcinolone acetonide (TA), polybrene, and all other reagents were purchased from Sigma (St. 
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Louis, MO) unless otherwise indicated.  Horseradish peroxidase-conjugated secondary 
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
 
Electroporation of siRNA.  siRNAs were purchased from Dharmacon, Inc. (Lafayette, CO). 
The sense strand sequences of the RNA duplexes used were as follows: Control siRNA (firefly 
luciferase, 5'-CGUACGCGGAAUACUUCGA(dTdT)-3'); KIF11 (5’-
AACUGAAGACCUGAAGACAAU(dTdT)-3’); BIM#1 (5’-
ACCGAGAAGGUAGACAAUU(dTdT)-3’), BIM#2 (5’-
CUACCUCCCUACAGACAGA(dTdT)-3’); BIM EL (5’-
CUCGAUCCUCCAGUGGGUA(dTdT)-3’); BIM EL + BIM L (5’-
CAGCACCCAUGAGUUGUGA(dTdT)-3’); BCL2#1 (5’AGAUAGUGAUGAAGUACAUUU-
3’); BCL2#2 (5’-GAAGUACAUCCAUUAUAAGUU-3’); BCL2#3 (5’-
GGGAGAUAGUGAUGAAGUAUU-3’).  Cells were washed twice with phosphate buffered 
saline (PBS) and resuspended in serum-free RPMI-1640 medium containing 25 mM HEPES (no 
phenol red or antibiotics) at 107 cells/mL.  A 200 µL aliquot of cells was added to a 0.2 cm gap 
electroporation cuvet (Bio-Rad, Hercules, CA), along with 10 µL of a 20 µM stock of siRNA, 
then incubated at room temperature for 20 minutes. Cells were then electroporated with a Bio-
Rad Gene Pulser using the indicated conditions, incubated for an additional 20 min and added to 
2 mL of the above medium (excluding aggregated cell debris) supplemented with 10% FBS. 
Thus, the final concentration of siRNA is 100 nM following electroporation.  The standard 
condition of 500 µF capacitance (see Results) achieved a pulse length of 7-8 ms. Vehicle (0.05% 
ethanol) or TA was added after the indicated recovery times. 
 
Cell cycle analysis and viability assays. Electroporated and drug treated 697 cells were 
harvested, washed with PBS and fixed with 70% ethanol.  After fixing for 18 h at 4ºC, cells were 
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collected by centrifugation and resuspended in 1 mL of staining solution containing 50 µg/mL 
propidium iodide, 1 mg/mL RNase A and 1 mg/mL glucose in PBS.  Cells were analyzed for 
DNA content using a Beckman Coulter XL flow cytometer after 2 h of staining. 10,000 cells 
were counted per sample.  Percentages of cells in sub-G0 or G2/M cell cycle fractions were 
determined using WinMDI software (Scripps Research Institute, La Jolla, CA).  Trypan blue 
exclusion assays were performed in triplicate, counting >200 cells per sample. 
 
Immunoblot analysis. Cells were washed once in PBS and lysed with RIPA buffer containing 
1× Complete Protease Inhibitors (Roche, Indianapolis, IN). 30-50 µg of each whole cell extract 
was electrophoresed on Novex 12% Tris-Gly PAGE gels (Invitrogen) and transferred to 
nitrocellulose membranes.  Immunoblots were performed using antibodies against Bim (1:20000 
dilution, cat. # 202000, Calbiochem, San Diego, CA), Bcl-2 (1:10000, clone 100, Upstate 
Biotechnology, Lake Placid, NY), and GAPDH (1:20000, clone 6C5, Research Diagnostics, 
Flanders, NJ) using standard methods, and detected using chemoluminescent horseradish 
peroxidase substrates (Pierce, Rockford, IL).  Densitometry analyses were performed by 
generating net intensity values using Kodak 1-D software (Rochester, NY). 
 
RT-PCR. Total RNA was purified using RNeasy columns (Qiagen, Valencia, CA).  RT-PCR 
was performed in 50 µL reactions using 100 ng RNA, 0.5 µM of each primer and an annealing 
temperature of 53ºC for 25 cycles.  All other PCR conditions and reagents were supplied and 
recommended by the manufacturer’s protocol for the Titan One-Step System (Roche).  Primer 
sequences for BIM were (forward: 5’-GAGAAGGTAGACAATTGCAG-3’; reverse: 5’-
GACAATGTAACGTAACAGTCG-3’) and for GAPDH were (forward: 5’-
CACCCATGGCAAATTCCATG-3’ and reverse: TCTAGACGGCAGGTCAGGT-3’).   
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Caspase analysis.  For the caspase-3 substrate cleavage assay, one transfection was performed 
for each data point.  Cells were washed with PBS, lysed and assayed in a 96-well plate using the 
EnzCheck Caspase-3 Assay Kit (Molecular Probes, Eugene, OR).  Fluorescence was measured at 
emission and excitation settings of 485 nm/530 nm with a Bio-Tek FL600 plate reader 
(Winooski, VT).  For immunofluoresence, 50,000 cells were spun onto microscope slides, fixed 
and permeabilized with 4% paraformaldehyde/0.1% Triton X-100, immunostained with anti-
active caspase-3 antibody diluted 1:50 (Cell Signaling Technology, Beverly, MA), and 
counterstained with DAPI.  Fluorescent detection was performed with the Vector Laboratories 
biotin/avidin system (Burlingame, CA) and AlexaFluor 488 (Molecular Probes, Eugene, OR).   
 
Lentivirus generation and infection.   The lentiviral transfer and packaging vectors were a 
generous gift from Dr. Xiao-Feng Qui.  Lentivirus production was conducted by co-transfection 
of HEK293T cells with four plasmids:  packaging defective helper construct (pMDLg/pRRE, 3 
µg), a Rev-expressing construct (pRSV-Rev, 3 µg), a construct expressing a heterologous 
envelope protein (pCMV-VSVg, 5 µg), and a transfer vector harboring a specific shRNA 
sequence under control of the H1 RNA polymerase III promoter (pH1UG/Luc-shRNA or 
pH1UG/Bim-shRNA, 10 µg).  Briefly, 3 x 106 HEK293T cells were seeded on 10 cm plates 24 h 
before transfection.  For each shRNA, 100 µL of Fugene-6 (Roche) was combined the four 
plasmids in 3 mL serum free RPMI-1640 medium.  The mixture was added dropwise onto the 
cells after a 30 min incubation and the cells were analyzed for green fluorescent protein (GFP) 
expression by fluorescence microscopy after 24 h.  At 48 h, virus containing cell supernatants 
were collected and centrifuged twice to eliminate transfer of cells.  shRNA-encoding pH1UG 
vectors were created by cloning annealed complementary oligonucleotides into BamH1 and 
Xho1 sites at the 3’ of the H1 RNA Polymerase III promoter.  The coding strand sequences of 
the shRNA-encoding oligonucleotides are as follows: Luciferase control (5’-




TTC-3’); and BIM  (5’-
GATCCCCGACTGAGAAGGTAGATAATTTTCAAGAGAAATTGTCTACCTTCTCGGTCT
TTTTC-3’).  The BIM shRNA sequence used was modeled after the BIM#1 siRNA sequence.  
The 697 cells were infected by adding 1 mL viral supernatant supplemented with 4 µg/mL 
polybrene to 5 x 104 cells in 24 well plates.  Viral supernatant was replaced with standard growth 
medium after 24 h, and infection efficiency was monitored by GFP expression after 48 h.  Viral 
titers were calculated by counting GFP-positive cells after infecting with serial dilutions of viral 
supernatant. 
 
Northern analysis.  Total RNA was prepared from shRNA-expressing cell lines using Tri 
reagent (Sigma) according to the vendor’s protocol.  30 µg of RNA were electrophoresed on a 
TBE-urea 15% acrylamide gel (Invitrogen) and transferred to a Zeta Probe nitrocellulose 
membrane (Bio-Rad, Hercules, CA).  The membranes were UV cross-linked and probed with an 
end-labeled Bim antisense probe (5’-[32P]AATTGTCTACCTTCTCGGTC-3’) at 42ºC for 18 h.  
For the two hybridization control oligonucleotides (perfect match and 2-base mismatch), the two 
complementary BIM shRNA-encoding oligonucleotides were used since wobble base-pairing in 





The pro-apoptotic Bcl-2 relative Bim has been shown to be upregulated by GC in GC-
sensitive lymphocytes, suggesting that Bim may function as an early sensor for intrinsic 
apoptosis (7,9,27).  To determine if there is a correlation between Bim induction and GC 
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sensitivity in human pre-B ALL cells, we monitored a panel of human pre-B ALL cell lines for 
viability in response to the potent GC, triamcinolone acetonide (TA) after 48 h and 72 h 
exposures (Fig. 1a,b).  Significant cell death was observed in the cell line 697 at low doses (5 
nM) after 48 h, but the other lines tested (Kasumi-2, Kopn-8, and Nalm-6) showed no effect after 
48 h and only slight (Kasumi-2, Kopn-8) or moderate (Nalm-6) cell death at the 72 h time point.  
We then compared the effect of TA on Bim protein levels in the sensitive and resistant cells (Fig 
1c).  We observed that the three major Bim proteins (BimEL, BimL, and BimS) (23) increased 
after 24 h in the 697 cells but not in the other pre-B ALL cell lines.  In addition, basal levels of 
the Bim proteins were low or undetectable in the GC-resistant lines.  To further explore the 
kinetics of Bim induction by GC, the 697 cells were also exposed to GC for shorter time points, 
showing rapid upregulation of the three Bim proteins after a 4 or 8 h exposure to 100 nM TA.   
Taken together, these data suggest that Bim expression and induction is a factor in determining 
the pro-apoptotic response to GC in pre-B ALL.   
We then sought to reduce Bim expression in 697 cells by RNAi. Use of synthetic short-
interfering RNA duplexes (siRNAs) has not been widely reported for lymphocytes, primarily due 
to the technical difficulty of nucleic acid transfection in non-adherent cultures.  It has previously 
been shown that, for lymphocytes, electroporation is a more efficient delivery method for 
synthetic nucleic acids than liposome-mediated transfection (30).  However, the cytotoxicity 
caused by the cellular stress of electroporation has often been too significant to perform 
downstream viability measurements.  It has previously been reported (30) that an siRNA against 
the KIF11 gene, which encodes the mitotic kinesin KSP (also known as Eg5), is an effective tool 
to optimize transfection conditions due to its ability to induce mitotic block.  In order to 
determine conditions for electroporating siRNAs into human 697 pre-B lymphocytes, we tested 
several RNA concentrations and capacitance settings using a KIF11-targeting siRNA.  After 48 
hours, cell cycle analysis was performed using propidium iodide staining and flow cytometry.  
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Under optimized settings (220 V/500 µF), the percentage of cells blocked in the G2/M stage was 
two-fold higher for the KSP siRNA as compared to a control siRNA (Fig 2a), indicating that the 
level of transfection was sufficient to explore biological phenotypes.  We also verified that RNA 
uptake occurred in over 90% of the cells under these transfection conditions using a nonspecific 
siRNA labeled with Cy3 (data not shown).  Importantly, the relatively mild electroporation 
conditions resulted in a minimal accumulation of sub-G1/G0 cells, indicating that this RNA 
delivery method caused negligible cell death and is therefore suitable for performing downstream 
viability studies. Finally, increasing the capacitance setting or the siRNA concentration did not 
further increase the percentage of cells blocked in G2/M (Fig. 2b). 
 24 hours after transfection with two BIM-targeting siRNAs, steady state levels of BimEL, 
BimL, and BimS were markedly reduced compared to a control siRNA sequence (Fig. 3a).   
Neither of the BIM-targeting siRNAs affected expression of the housekeeping protein GAPDH 
(Fig. 3a), or other Bcl-2 family members Bax and Bad (data not shown). To determine if the 
siRNA can reduce the level of Bim even after its expression is upregulated by GC, we treated the 
cells with TA (100 nM) 24 h after siRNA electroporation.  The 24 h recovery after 
electroporation allows for degradation of existing Bim protein, whose rapid turnover rate can be 
attributed in part to ubiquitin-proteasome processing (31).  Both siRNAs caused a marked 
reduction in not only basal Bim expression, but also the TA-induced levels of the three major 
splice variants relative to a control sequence (Fig 3a, right panel).  The more potent Bim siRNA 
(sequence 2) caused a 70 % reduction in basal BimEL (n=4) and a 30% reduction in TA-induced 
BimEL (n=2) (Fig. 3a, right panel, compare lanes 1 and 2 to lanes 5 and 6).  To explore the 
RNAi effect at the mRNA level, we performed RT-PCR on total RNA isolated from siRNA-
transfected 697 cells.  The use of endpoint RT-PCR allows for visualization of all three major 
splice variants.  Immediately following a 20 min post-electroporation recovery incubation (see 
Materials and Methods), the transfected cells were treated with vehicle or TA (100 nM), then 
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harvested 2.5, 5, or 7.5 h later.  The mRNAs corresponding to the three major splice variants 
were effectively reduced by the BIM-targeting siRNA only 2.5 h after electroporation, and 
reached near-maximal silencing by that early time point as further incubation to 7.5 h had little 
additional effect. Treatment of the cells with TA caused BIM mRNA induction relative to 
vehicle-treated controls, which was effectively abrogated by the siRNA (Fig 3b).   
 To determine whether targeting Bim affects the apoptotic machinery in the 697 cells, we 
analyzed cells for caspase-3 activation (cleavage) and caspase-3 enzyme activity.  Cells were 
electroporated as above, allowed to recover for 24 h (to allow for the degradation of pre-existing 
Bim protein), then treated with TA (5 nM) 24 h.  This low, physiologically-relevant GC 
concentration corresponds to the approximate Kd of TA for the receptor (32). After an 18 h drug 
exposure, cells were immunostained with an antibody specific for the active (cleaved) form of 
caspase-3.  Silencing of Bim reduced TA-induced caspase-3 activation, reflecting a decrease in 
activity of its upstream activator, caspase-9 (Fig 4a).  To confirm these results, we also 
monitored the enzymatic activity of caspase-3 by assaying for cleavage of the fluorescent 
substrate, DEVD-Rhodamine-110, as described (33).  BIM siRNA reduced GC-induced caspase-
3 activity relative to the control siRNA in each of three independent transfections, averaging a 
50% reduction in substrate cleavage (Fig 4b).   
To determine the effect of BIM-targeting siRNAs on GC sensitivity, we transfected both 
siRNAs (#1 and #2) into the 697 cells, then treated siRNA-transfected 697 cells with TA (5 nM) 
24 h after electroporation.  The cells were fixed 48 h after addition of the drug (a time point 
chosen to result in 60% cell death, see Fig. 1a), and apoptotic cells were detected by staining 
with propidium iodide followed by flow cytometry (Fig. 4c).  The more potent of the two 
sequences (#2, see Fig. 3a) decreased the percentage of cells containing sub G0/G1 by 
approximately 50%, while the less potent siRNA (#1) showed less of an effect.  These data were 
also verified by Trypan blue exclusion and by staining live cells with another viability dye, 7-
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aminoactinomycin-D (data not shown).  Taken together, these data demonstrate that GC-
mediated induction of Bim is an essential signaling event in GC-induced apoptosis in a human 
pre-B ALL model. 
 Previous work has made functional distinctions among the major Bim isoforms.  In order 
to determine the relative contributions of BimEL, BimL and BimS in GC-induced apoptosis, we 
designed siRNAs that target only BIM EL or BIM EL and BIM L, but not BIM S. It is not 
possible to target BIM S independently due to the lack of a unique sequence.  On the immunoblot 
shown in Fig. 5a, an overexposed image is shown for BimL and BimS to highlight siRNA effects 
on these proteins.  Compared to BIM siRNA#2, which decreased levels of all three proteins (Fig 
5a, lane 3), triplicate transfections of the two splice-variant specific siRNAs showed that these 
reagents successfully reduced expression of only their target isoforms.  These data were 
corroborated by RT-PCR, which was performed 4 h after transfection (Fig. 5b).  To make BIM L 
and BIM S mRNA more easily detectable by RT-PCR (Fig 5b), the post-electroporation recovery 
was performed in the presence of TA to induce their expression.  To determine effects of the 
splice variant-specific siRNAs on GC sensitivity (Fig 5c), triplicate transfections were performed 
followed by a 48 h TA exposure and cell cycle analysis as in Fig. 4c. Similar to the data in Fig. 
4c, the siRNA targeting all three Bim proteins reduced the percentage of sub-G0 cells from 53% 
to 20% (a 62% decrease in cell death).  Both of the isoform-specific siRNAs also decreased GC-
induced cell death, albeit to a lesser extent (39% and 36%, respectively).  These data suggest that 
all three major splice variants contribute to GC-induced apoptosis of human pre-B ALL cells. 
 To explore the possibility of creating a stable cell line in which partial GC resistance is 
acquired through a reduction in Bim levels, we designed a short hairpin RNA (shRNA) targeting 
BIM or a control sequence.  These sequences were used to produce lentiviral vectors which 
express shRNA under control of the H1 RNA polymerase III promoter (34).  An infection rate of 
nearly 100% was achieved in the 697 cells, as indicated by expression of a green fluorescent 
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protein (GFP) marker, which is encoded by the lentivirus under control of an independent CMV 
promoter (Fig. 6a).  GFP expression remained constant and complete in the population 8 weeks 
after infection, indicating that the provirus is stably integrated (data not shown).  A northern 
hybridization using a 32P-labeled probe specific for the BIM shRNA revealed the presence of the 
Dicer-processed 21-nucleotide RNA in cells infected with the BIM shRNA virus, but not in cells 
infected with a virus encoding an shRNA against firefly luciferase (Fig. 6b).  In addition, the 62-
nucleotide unprocessed shRNA was not detected, indicating that processing of the shRNA to the 
mature siRNA was rapid.  Similar to the data generated with the BIM-targeting synthetic siRNA 
(Fig. 3a), immunoblot analysis revealed effective Bim silencing in both the basal state and after 
inducing Bim expression with TA (Fig. 6c).  In addition, the BIM shRNA-infected cell line also 
effectively inhibited TA-induced caspase-3 activation (Fig. 6d).   
 The ratio of pro-apoptotic and anti-apoptotic Bcl-2 family members (“the Bcl-2 
rheostat”) (35)  often controls the decision of a tumor cell to commit to irreversible intrinsic 
apoptosis.  Bim was first isolated as a Bcl-2 binding protein (23) and its deletion prevents defects 
caused by Bcl-2 deficiency in mice (36).  Given the previous observation that Bcl-2 (but not Bcl-
XL) was reduced in response to GC in 697 cells (2), we sought to explore the role of the 
Bim/Bcl-2 ratio in RNAi-mediated GC resistance.  We targeted BCL2 by electroporation of 
synthetic siRNA, achieving a marked reduction in Bcl-2 protein (Fig. 7a).  BCL2-targeting 
siRNA was then electroporated into the 697 cells stably expressing control or BIM-targeting 
shRNAs.  GC sensitivity was assayed by 48 h TA exposure followed by cell cycle analysis as in 
previous figures (Fig. 7b).  In the absence of TA, the BCL2 siRNA had a modestly toxic effect 
on both lentiviral-infected cell lines.  In the drug-treated cells, silencing Bcl-2 did not 
significantly modulate the level of GC resistance caused by BIM shRNA.  These data suggest 
that Bim may function independently from Bcl-2 in GC-induced apoptosis.  
 





In this study, we have presented data demonstrating that GC-mediated induction of Bim 
is a critical signaling event in GC-induced apoptosis of human pre-B ALL cells.  Under 
conditions where the levels of Bim proteins were reduced by 70% in the basal state and 30% in 
the GC-induced state (Figs. 3a and 6c), TA treatment in 697 pre-B ALL cells resulted in 
approximately 50% fewer apoptotic cells (Figs. 4c and 7b) as well as inhibition of caspase-3 
(Figs. 4b and 6d).  Using the powerful tool of splice variant-specific siRNAs, we have also 
demonstrated that all three major Bim proteins apparently contribute to apoptosis induction.  
Since GC-mediated Bim upregulation occurs in other GC-sensitive leukemic cell lines as well 
(namely, S49, CEM-C7 and WEHI7.2 cells) (9,27), we propose that this transcriptional event is a 
primary mechanism of apoptotic induction in this clinically-important signaling pathway.  In this 
respect, this mechanism parallels many DNA damage pathways, during which p53 induces 
apoptosis by upregulating Noxa and Puma (37,38).  Our findings do not exclude roles for other 
BH3-proteins in this pathway; indeed it must be noted that deletion of the PUMA gene causes a 
delayed response to dexamethasone in mouse thymocytes (39).   However, PUMA does not 
appear to be a GR target gene in 697 pre-B ALL cells (7) or murine S49 T-cells (9).   
Interestingly, this study suggests that Bim may be functioning independently of Bcl-2 in 
GC-induced apoptosis.  Reducing Bcl-2 protein approximately 50% did not suppress the GC 
resistance caused by BIM shRNA.  This was somewhat unexpected given the importance of the 
Bim/Bcl2 ratio in apoptotic pathways in a mouse knockout model (36), and the fact that Bcl-2 
overexpression prevents Bim-induced cell death in mouse fibroblasts (40).  The BH3-only 
proteins promote apoptosis by directly interacting with other Bcl-2 family members through the 
BH3 domain, an amphipathic helix that docks in a hydrophobic pocket formed by the BH1 
and BH2 domains (41).  Bim proteins have been shown to have the ability (a) to bind to Bcl-2, 
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preventing Bcl-2 from inhibiting the pro-apoptotic Bax from inserting in the mitochondrial 
membrane, and (b) directly to Bax, in which case they would function as direct activators of 
apoptosis (40).  The lack of effect of the BCL2 siRNA opens the possibility that Bim might 
function through Bax or Bak.  Interestingly, the lymphoproliferative phenotype of bim(-/-) mice is 
similar to that of bax-/bak- double knockout mice (39,42).   However, an alternative explanation 
for our result is that Bcl-2 is still in excess despite siRNA treatment, above an unachieved 
threshold that must be reached in order to silence the fraction that is affected by Bim binding. 
While it has been established that GC regulates BIM mRNA transcription, there is also 
the possibility that GC might regulate Bim protein through post-translational mechanisms.  
Indeed, BimEL phosphorylation is an early event in growth factor deprivation (21).  However, it 
is unlikely that BimEL phosphorylation is a factor in the 697 cells given that GC treatment does 
not affect its gel migration (Fig. 1 and unpublished observations).  It has also yet to be 
determined whether GC treatment affects the subcellular location of BimEL and BimL, which 
have been shown to be released from sequestration to the dynein motor complex upon cytokine 
withdrawal or ultraviolet radiation exposure (25).  Although Bim subcellular localization should 
be investigated in the future, it is worth noting that the concept of mitochondrial translocation of 
Bim is controversial as it has recently been shown that most of the Bim protein in healthy resting 
T cells is already localized to the mitochondria (26).   
Previous studies demonstrated that the upregulation of BIM is indirect; i.e. not caused by 
direct binding of the GR to the BIM promoter.  First, the promoter does not contain a 
glucocorticoid response element (GRE) (43).  More significantly, new protein synthesis is 
required for BIM mRNA induction by GC (9).  Given that a functional DNA binding GR is 
required for GC-induced apoptosis (44), it is likely that induction or repression of (an)other GR 
target gene(s) must occur as a prerequisite to the effects on Bim.  Indeed, the forkhead 
transcription factor FHKRL1, which is known to target the BIM gene (45), is upregulated by GC 
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in 697 cells (7).  However, it must be noted that targeting FHKRL1 by siRNA did not affect GC-
induced apoptosis in 697 cells (unpublished observations).   
Consistent with the combinatorial nature of GR-mediated transcriptional effects (46), 
other GR target genes might also serve as apoptotic signaling intermediates in addition to BIM.
Although RNAi inhibition of GR target genes has not previously been reported to our 
knowledge, it has been reported that forced overexpression of a number of known GR target 
genes, including catalase (47) and DIG2 (48) modulates the apoptotic response.  Now that the 
GR transcriptome has been characterized by microarray experiments in numerous model systems 
(46), it will be possible to perform systematic RNAi screens towards uncovering the other 
critical signaling intermediates in this pathway.  Since glucocorticoid resistance (49) and poor 
prognosis (50) are associated with low GR content in ALL,  bypassing the receptor by targeting 
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Figure 1.  GC sensitivity and Bim induction in human pre-B ALL cell lines. 
A, B, The cell lines 697 (triangles), Nalm-6 (closed circles), Kasumi-2 (open circles), and Kopn-
8 (squares) were treated with 0.5-500 nM TA for 48 h (A) or 72 h (B) and assayed for cell 
viability by Trypan blue exclusion. Error bars represent the SEM of three assays.  C, The panel 
of pre-B ALL cells was treated with vehicle or 100 nM TA for 24 h and whole cell lysates were 
immunoblotted with Bim and GAPDH antibodies. The positions of the three major Bim proteins 
are indicated.  D, The 697 cell line was treated with vehicle or 100 nM TA for 4 or 8 hours and 
immunoblotted as in C.
Figure 2. Optimization of siRNA electroporation in 697 cells. A, Cells were electroporated 
with siRNAs targeting firefly luciferase (“Ctrl siRNA”) or KSP at 200 V / 500 µF.  The cells 
were fixed after 48 h and subjected to propidium iodide staining and flow cytometry.  The G1 
and G2/M peaks of the cell cycle are indicated.  B, Quantitation of cells in G2/M arrest after 
electroporating cells with control (white bars) or KSP (black bars) siRNAs under different 
conditions, representative of two trials.  
 
Figure 3. BIM-targeting siRNAs reduce basal and GC-induced BimEL, BimL and BimS 
proteins and the corresponding mRNAs in 697 pre-B ALL cells.  A, Cells were transfected 
with two unique BIM siRNA sequences (BIM#1 and BIM#2) and the control luciferase siRNA 
(“Ctrl”).  For the experiment shown in the left panel, cells were harvested and lysed 24 h after 
transfection.  Right panel, cells were treated with vehicle or 100 nM TA as indicated 24 h after 
transfection and harvested after a 24 h treatment.  The densitometry data for BimEL are above 
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the image.  Both siRNAs reduced the basal as well as the TA-induced protein levels and that 
BIM#2 is more potent of the two RNA duplexes. B, Cells were treated with vehicle or 100 nM 
TA for 2.5, 5, or 7.5 h immediately after transfection with BIM-targeting siRNA (BIM#1).  Total 
RNA was isolated and subjected to RT-PCR using primers specific for BIM (left) or GAPDH 
(right).  The positions of the three major splice variants are indicated. 
 
Figure 4. BIM siRNA inhibits GC-induced caspase-3 activity and confers partial resistance 
to GC in 697 cells. A, Cells were transfected with control (left) or BIM (right) siRNAs, followed 
24 h later by treatment with 5 nM TA.  After an additional 24 h, cells were spun onto microscope 
slides, fixed, permeabilized, and subjected to immunofluorescence using an antibody specific for 
cleaved (activated) caspase-3.  Bound antibody was detected with AlexaFluor 488 (green) and 
nuclei were counterstained with DAPI (blue).  B, Cells were transfected and treated with vehicle 
or TA as above, followed by cell lysis and assayed for cleavage of the fluorescent caspase-3 
substrate DEVD-Rhodamine-110. Error bars represent SEM of three assays. C, Triplicate 
transfections with the control siRNA (white bars), BIM#1 siRNA (striped bars), or BIM#2
siRNA (black bars),  followed 24 h later by addition of vehicle or 5 nM TA was performed as 
above.  Cells were fixed after a 48 h treatment and subjected to propidium iodide staining and 
flow cytometry.  Apoptotic (sub-G0) cells were scored using WinMDI software.  Error bars 
represent the SEM of three measurements, each originating from an independent siRNA 
transfection. 
 
Figure 5. Generation of splice variant-specific BIM siRNAs. A, siRNA duplexes specific for 
BIM splice variants were designed and transfected in triplicate, followed 24 h later by 
immunoblotting with anti-Bim and anti-GAPDH antibodies.  siRNAs used in this experiment 
targeted firefly luciferase (“Ctrl”, lanes 1 and 2), all three major splice variants (“all”, BIM si#2, 
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lane 3), BimEL only (lanes 4-6), or BimEL + BimL (lanes 7-9). B, Cells were transfected as 
above, immediately followed by treatment with 100 nM TA.  Cells were harvested after 4 hours 
and subjected to RT-PCR using primers specific for BIM or GAPDH as in Fig. 3b.  C, siRNAs 
were assayed for effect on GC sensitivity as in Fig. 4c.  Control (luciferase), white bars; BIM 
si#2, black; BimEL-only siRNA, striped; BimEL+BimL siRNA, dotted. 
 
Figure 6. Lentiviral delivery of Bim shRNA. A, The 697 cells were infected with a lentivirus 
encoding Bim shRNA and analyzed by fluorescence microscopy after 48 h for expression of 
green fluorescent protein (GFP). B, Total RNA (30 µg) from cells infected with lentivirus 
encoding Bim (“Bim”) or control (“Ctrl”, luciferase) shRNAs was subjected to northern 
hybridization with a probe complementary to the antisense strand of Bim shRNA.  The gel was 
stained with ethidium bromide (“EtBr”) as a loading control before transfer.  PM (perfect match), 
control oligonucleotide with complete complementarity to the probe; MM (mismatch), control 
oligonucleotide which is complementary to the probe except for two mismatched bases. C, Cell 
lines stably expressing control or Bim shRNAs were analyzed for effects on basal (left image) 
and TA-induced (right) Bim protein levels by immunoblot.  Each cell line was treated with 
vehicle, 5, or 100 nM TA as indicated and the densitometry data for BimEL (above image) show 
that the BIM shRNA-expressing cells induced Bim protein to a level that was >30% lower than 
the control siRNA.  D, Control (white bars) and BIM shRNA (black bars) expressing cells were 
subject to caspase-3 activity assay after 24 h vehicle or TA treatment as in Fig. 4b. 
 
Figure 7. Effect of reducing Bcl-2 protein levels on GC resistance caused by BIM shRNA.  
A, Three siRNAs targeting BCL2 mRNA were tested on 697 cells (as in Fig. 3a) and protein 
extracts were immunoblotted using antibodies against Bcl-2 and GAPDH.  B, Cells stably 
expressing control shRNA (solid bars) or BIM shRNA (dotted bars) were transfected with 
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control siRNA (white bars) or BCL2 siRNA (BCL2#1, black bars) followed by a 48 h vehicle or 
TA treatment as in Figs. 4c and 5c.  Error bars represent the SEM of three assays. 
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